Cipher Pharmaceuticals (TSE:CPH) Reaches New 1-Year High – Should You Buy?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s share price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as C$20.39 and last traded at C$20.12, with a volume of 66167 shares changing hands. The stock had previously closed at C$17.87.

Cipher Pharmaceuticals Stock Performance

The company has a current ratio of 1.12, a quick ratio of 2.67 and a debt-to-equity ratio of 4.36. The firm has a market capitalization of C$508.91 million, a P/E ratio of 19.17 and a beta of 0.89. The company has a 50-day moving average of C$17.24 and a 200-day moving average of C$15.54.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. Cipher Pharmaceuticals had a return on equity of 24.23% and a net margin of 54.37%.The company had revenue of C$17.39 million for the quarter. On average, equities analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.